Lung caught in Nilutamide treatment

Eva Patrícia Lourenço, Hipólito Nzwalo, Mário Rui Sampaio, Helena Brito

Centro Hospitalar do Algarve-
Hospital de Faro, Faro,
Portugal

Correspondence to

Dr Eva Patrícia Lourenço,
mariosampaio@hotmail.com

Accepted 18 August 2016

DESCRIPTION

An 86-year-old male patient was attended with dyspnoea for 2 weeks, with progressive worsening, dry cough and decreased appetite. He had a personal history of prostate cancer diagnosed 2 years before and dyslipidaemia. He denied smoking history, exposure to inhaled toxic substances or family history of chronic lung disease. The patient was receiving treatment with rosuvastatin 10 mg and nilutamide 150 mg which was started 1 month earlier. On physical examination we found the patient with globally decreased breath sounds and crackles at the base of the right hemithorax. Laboratory tests showed no other abnormalities besides C-reactive protein 69 g/L and slight hypoxaemia.

The chest X-ray showed bilateral interstitium infiltrates with slight effacement of the costophrenic angles and elevation of the right hemicupula (figure 1A). The thorax CT scan was consistent with interstitial pneumonitis (figure 1B, C). Serological tests for viral atypical organisms, anti-nuclear antibodies, ACE inhibitors and antineutrophil cytoplasmic antibodies were carried out but with negative results. Pulmonary function tests, alveolar lavage and lung biopsy were not performed. The treatment with nilutamide was discontinued and the patient was started on bronchodilator therapy and prednisolone 40 mg/day with clinical improvement after 3 days of hospitalisation and discharge from hospital at day 14 with normal clinical observation, gasimetric normalisation, negative RCP and improved chest X-ray imaging. Nilutamide is a non-steroidal antiandrogen, which competitively inhibits the binding of androgens to the androgen receptor.¹ Interstitial pneumonitis is an extremely rare, although

reversible, adverse reaction to non-steroidal antiandrogen treatment, being described in 1–2% of the patients taking the drug.² The mechanisms by which non-steroidal antiandrogens cause pulmonary disease remain unclear.³

The onset of symptoms was reported 2–8 months after the beginning of the treatment.² The prognosis of drug-induced pneumonitis is relatively good and can be treated with the withdrawal of the drug with or without the association of steroids.³

Learning points

- ▶ Nilutamide is a non-steroidal antiandrogen, related to bicalutamide and flutamide.
- ▶ Interstitial pneumonitis is an extremely rare adverse reaction described in 1–2% of the patients taking the drug.
- ▶ The prognosis is relatively good and can be treated with the withdrawal of the drug with or without steroid treatment.

Competing interests None declared.

Patient consent Obtained.

Provenance and peer review Not commissioned; externally peer reviewed.

REFERENCES

- 1 British Columbia cancer agency, M. *Cancer drug manual: nilutamide*. Columbia: BC Cancer Agency, 2007.
- 2 Nomura M, Fujimoto N, Matsudo T. Interstitial pneumonitis related to flutamide monotherapy for prostate cancer. *J Urol* 2004;171:798–800.
- 3 Shoi K, Yoshida M, Nakamura M. Successful recovery from interstitial pneumonitis, induced by bicalutamide and leuporelin acetate given as treatment for prostate. *Acta Urol Jpn* 2005;51:211–4.

Figure 1 (A) Chest X-ray on admission: Bilateral interstitium infiltrates with slight effacement of the costophrenic angles and elevation of the right hemicupula. (B) Coronal and (C) Cross-section of thorax CT showing accentuation of interstitium with several parenchymal infiltrates, outlining condensation zone in the lower lobe of the right lung, with thin pleural effusion.

CrossMark

To cite: Lourenço EP, Nzwalo H, Sampaio MR, et al. *BMJ Case Rep* Published online: [please include Day Month Year] doi:10.1136/bcr-2016-216590

Copyright 2016 BMJ Publishing Group. All rights reserved. For permission to reuse any of this content visit <http://group.bmj.com/group/rights-licensing/permissions>.
BMJ Case Report Fellows may re-use this article for personal use and teaching without any further permission.

Become a Fellow of BMJ Case Reports today and you can:

- ▶ Submit as many cases as you like
- ▶ Enjoy fast sympathetic peer review and rapid publication of accepted articles
- ▶ Access all the published articles
- ▶ Re-use any of the published material for personal use and teaching without further permission

For information on Institutional Fellowships contact consortiasales@bmjgroup.com

Visit casereports.bmj.com for more articles like this and to become a Fellow